IMMUNOVANT, INC. Shareholders' Equity
IMMUNOVANT, INC. (IMVT) had Shareholders' Equity of $735.39 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $735.39M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $852.59M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $986.13M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $519.71M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $735.39M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $852.59M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $986.13M 10-Q · filed 2026-02-06 | |
| 2025-09-30 | $519.71M 10-Q · filed 2026-02-06 | |
| 2025-06-30 | $608.54M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $707.45M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $352.62M 10-Q · filed 2026-02-06 | |
| 2024-09-30 | $449.05M 10-Q · filed 2026-02-06 | |
| 2024-06-30 | $544.66M 10-Q · filed 2026-02-06 | |
| 2024-03-31 | $617.76M 10-K · filed 2026-05-20 | |
| 2023-12-31 | $679.34M 10-Q · filed 2025-02-06 | |
| 2023-09-30 | $251.81M 10-Q · filed 2025-02-06 | |
| 2023-06-30 | $299.87M 10-Q · filed 2025-02-06 | |
| 2023-03-31 | $362.49M 10-K · filed 2026-05-20 | |
| 2022-12-31 | $414.68M 10-Q · filed 2024-02-12 | |
| 2022-09-30 | $395.75M 10-Q · filed 2024-02-12 | |
| 2022-06-30 | $436.49M 10-Q · filed 2024-02-12 | |
| 2022-03-31 | $469.82M 10-K · filed 2025-05-29 | |
| 2021-12-31 | $505.15M 10-Q · filed 2023-02-03 | |
| 2021-09-30 | $536.40M 10-Q · filed 2023-02-03 | |
| 2021-06-30 | $365.53M 10-Q · filed 2023-02-03 | |
| 2021-03-31 | $391.48M 10-K · filed 2023-05-22 | |
| 2020-12-31 | $414.15M 10-Q · filed 2022-02-04 | |
| 2020-09-30 | $438.41M 10-Q · filed 2022-02-04 | |
| 2020-06-30 | $267.77M 10-Q · filed 2022-02-04 | |
| 2020-03-31 | $94.07M 10-K · filed 2022-06-08 | |
| 2019-12-31 | $111.86M 10-Q · filed 2021-02-16 | |
| 2019-09-30 | -$23.28M 10-Q · filed 2021-02-16 | $5.00M 10-Q · filed 2019-11-13 |
| 2019-06-30 | -$12.11M 10-Q · filed 2021-02-16 | $5.00M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $7.34M 10-K · filed 2021-06-01 | $24.10K 10-Q · filed 2019-06-12 |
| 2018-12-31 | $7.96M 10-Q · filed 2020-02-14 | $24.55K 10-Q · filed 2019-06-12 |
| 2018-09-30 | $2.32M 10-Q · filed 2020-02-14 | |
| 2018-07-06 | -$411.00K 10-K · filed 2020-06-29 | |
| 2018-06-30 | -$411.00K 10-Q · filed 2020-02-14 | |
| 2018-03-31 | -$1.50M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |